Literature DB >> 22203759

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

Panagiotis A Konstantinopoulos, Stephen A Cannistra.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22203759     DOI： 10.1200/JCO.2011.40.1489

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.

Authors:  Molly S Daniels; Sheri A Babb; Robin H King; Diana L Urbauer; Brittany A L Batte; Amanda C Brandt; Christopher I Amos; Adam H Buchanan; David G Mutch; Karen H Lu
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 2.  An update on PARP inhibitors--moving to the adjuvant setting.

Authors:  Amir Sonnenblick; Evandro de Azambuja; Hatem A Azim; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

Review 3.  Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.

Authors:  Fiona J Collinson; Jenny Seligmann; Timothy J Perren
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

4.  Major clinical research advances in gynecologic cancer in 2012.

Authors:  Dong Hoon Suh; Jae-Weon Kim; Kidong Kim; Hak Jae Kim; Kyung-Hun Lee
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

5.  Ovarian cancer: emerging molecular-targeted therapies.

Authors:  Carole Sourbier
Journal:  Biologics       Date:  2012-06-20

Review 6.  The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.

Authors:  Raquel E Reinbolt; John L Hays
Journal:  Front Oncol       Date:  2013-10-01       Impact factor: 6.244

Review 7.  Cytotoxic and targeted therapy for hereditary cancers.

Authors:  Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2016-08-23       Impact factor: 2.857
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.